Employees: 231
Size ProKidney (PROK) is a United States Health Care company (Biotechnology) with a market value of $314M, the 3036th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.04 on 18 Nov 2026.
Performance Over six months the shares fell 38.5%, against -24.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +7.3%); the operating margin is -24,830.3% (peer median -115.0%).
Valuation It trades at 1,625.4× enterprise value to sales against a peer median of 5.3× (2nd most expensive of 15).
Capital Return on invested capital runs 98.8 points below its cost of capital (14.4% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $775,000 | $893,000 | $76,000 | $0 | $0 |
| Revenue growth | — | +1,075% | — | — | — |
| Gross profit | -$5.03M | -$4.83M | -$4.26M | -$3.17M | -$3.04M |
| EBITDA | -$187M | -$159M | -$174M | -$148M | -$150M |
| Net income | -$103M | -$69.0M | -$61.2M | -$35.5M | -$108M |
| Free cash flow | -$168M | -$135M | -$156M | -$124M | -$78.9M |
| Capital expenditure | $14.6M | $15.2M | $29.5M | $34.2M | $1.85M |
| Total debt | $3.25M | $4.04M | $3.24M | $4.41M | $2.40M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PROK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.8% | -4.7% | 3rd lowest of 20 |
| 6-month return | -38.5% | -24.7% | 6th lowest of 20 |
| Distance from 52-week high | -60.8% | -52.1% | 7th lowest of 20 |
| Revenue growth (TTM) | +4.2% | +7.3% | 6th lowest of 13 |
| Operating margin | -24,830.3% | -115.0% | 2nd lowest of 15 |
| EV / Sales | 1,625.4× | 5.3× | 2nd most expensive of 15 |
| ROIC minus cost of capital | -98.8 pp | -22.1 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | 1,625.4× | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | 9.5× | n/a | n/a |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | 588.9× | n/a | n/a |
| Cuorips 4894.T | Japan | $309M | -10% | -80% | -1,765% | 602.9× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $304M | -21% | -50% | -474% | 11.4× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $303M | -18% | +7% | 10% | 1.0× | 2.6% | +19.1% |
| Greenwich LifeSciences GLSI | United States | $302M | -25% | n/a | n/a | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $301M | +35% | n/a | n/a | n/a | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |